CDKN2A and pancreatic neoplasm: Insulin-like growth factor 1 (IGF1) receptor inhibitor, which potently inhibits the PI3K effector protein kinase B (AKT), synergizes with palbociclib to suppress growth and induce senescence in p16INK4A-deficient pancreatic cancers [96].